MedTrace Logo

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

NCT03890289 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-11-21

Study results available
· View outcomes & findings →

Summary

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease \[no response or response lasting less than 6 months at any previous line of treatment\] or with a proven disease relapse) at least 2 previous lines of treatment, including any antibody directed against the CD20 antigen-containing chemotherapy, will undergo a combined chemo-free treatment with obinutuzumab and idelalisib.

Conditions

Interventions

DRUG

Idelalisib

Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma

DRUG

Obinutuzumab

Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Pierluigi Zinzani, Prof. · Bologna - Policlinico S.Orsola-Malpighi - Istituto di Ematologia "Seragnoli"

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-18
Primary Completion
2021-04-29
Completion
2023-05-10

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03890289 on ClinicalTrials.gov